Skip to main content
Clinical Trials/NCT01463410
NCT01463410
Terminated
Not Applicable

Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler

Skyline Diagnostics BV5 sites in 4 countries264 target enrollmentOctober 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Myeloid Leukemia (AML)
Sponsor
Skyline Diagnostics BV
Enrollment
264
Locations
5
Primary Endpoint
Acceptance Criteria
Status
Terminated
Last Updated
12 years ago

Overview

Brief Summary

This clinical study will demonstrate the accuracy of the chromosomal aberration and gene mutation markers of the AMLProfiler molecular diagnostic assay and generate clinical performance data to support a Pre-Market Approval (PMA) submission to the Food and Drug Administration for in vitro diagnostic use within the United States of America.

The objective is to demonstrate the positive and negative percent agreement of each marker by comparing AMLProfiler results from multiple clinical participating sites with data generated using a laboratory developed bi-directional sequencing method generated at the molecular diagnostic reference lab.

The AMLProfiler assay is a qualitative in vitro diagnostic test for the detection of AML or APL specific chromosomal aberrations (specific recurrent translocations and inversions), as well as expression of specific genetic markers in RNA extracted from bone marrow aspirates of patients with Acute Myeloid Leukemia.

Registry
clinicaltrials.gov
Start Date
October 2011
End Date
March 2013
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Skyline Diagnostics BV
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects with a cytopathologically confirmed diagnosis of AML subjects with refractory anemia with excess of blasts (RAEB) according to the WHO 2008 classification
  • Written informed consent

Exclusion Criteria

  • Subjects without a cytopathologically confirmed diagnosis of AML subjects with refractory anemia with excess of blasts (RAEB) according to the WHO 2008 classification
  • \< 18 years
  • Without written informed consent

Outcomes

Primary Outcomes

Acceptance Criteria

Time Frame: Sample taken at initial visit with no follow up (Day 1)

The acceptance criteria based on lower level of the 95% CI of the positive or negative percent agreement for all markers.

Study Sites (5)

Loading locations...

Similar Trials